| Description |
Myostatin-IN-1 is a potent myostatin inhibitor (IC50 of 0.19, 0.63, 0.89 and 1.6 μM for myostatin, GDF-11, activin A and TGF-β1, respectively). Myostatin-IN-1 increases the tibialis anterior muscle mass in mice. Myostatin-IN-1 can be used for researching the prolonged inactivation of myostatin in skeletal muscle[1].
|
| Related Catalog |
|
| Target |
IC50: 0.19 μM (myostatin), 0.63 μM (GDF-11), 0.89 μM (activin A), 1.6 μM (TGF-β1)[1]
|
| In Vitro |
Myostatin-IN-1 (MID-35) (50 µM; 400 min) possesses complete proteolytic stability, and can survive 99 and 97% of the intact form incubated for 400 min in trypsin or α-chymotrypsin solution[1].
|
| In Vivo |
Myostatin-IN-1 (0.75 mM; i.m.; single) can significantly induce the increase in tibialis anterior (TA) muscle mass in C57BL/6J mice[1]. Animal Model: C57BL/6J mice (8 weeks)[1] Dosage: 0.75 mM Administration: i.m.; single Result: Significantly induced the increase in tibialis anterior (TA) muscle mass in C57BL/6J mice.
|
| References |
[1]. Takayama K, et al. Development of Myostatin Inhibitory d-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice. ACS Med Chem Lett. 2022;13(3):492-498. Published 2022 Feb 14.
|
